New Hope for Hearts: XVIVO Trial Boosts Organ Viability

TORONTO, ON – April 22, 2026 – A major hurdle in heart transplantation may soon be overcome, as new clinical trial data suggests a novel technology can significantly extend the life of donor hearts outside the body. Medtech company XVIVO has announced promising preliminary results from its PRESERVE Trial, demonstrating that its investigational hypothermic oxygenated perfusion (HOPE) system successfully preserved hearts for longer than the standard four-hour window, a development that could dramatically expand the pool of available organs and offer new hope to thousands of patients on transplant waitlists.

The findings, which XVIVO intends to submit to the U.S. Food and Drug Administration (FDA) later this year for Pre-Market Approval (PMA), represent a potential paradigm shift in a field long constrained by the unforgiving logistics of organ preservation.

A Race Against the Clock

For decades, the standard of care for transporting a donor heart has been static cold storage—placing the organ on ice in a cooler. While simple and effective for short durations, this method puts a strict four-hour time limit on the organ's viability. This narrow window severely restricts the geographic distance between donor and recipient and forces transplant teams to make rapid, high-stakes decisions. Consequently, a staggering number of donated hearts are never used.

Globally, only an estimated two out of every ten donated hearts are ultimately transplanted. Many are deemed too risky, belonging to what are known as extended-criteria donors (ECD). These hearts may come from older individuals or those with other risk factors, making them more susceptible to damage during transport. The current preservation method offers little buffer, leading transplant teams to decline organs that might otherwise be life-saving. This bottleneck has created a dire shortage, with 3,456 people currently on the heart transplant waitlist in the U.S. alone.

"For decades, organ preservation has been a limiting factor in heart transplantation, with approximately one in three DBD [donation after brain death] and one in five DCD [donation after circulatory death] hearts ultimately being transplanted,” said Dr. Victor Pretorius, a cardiothoracic surgeon at Emory Healthcare and the Principal Investigator of the PRESERVE Trial.

Redefining Preservation with HOPE

XVIVO's technology aims to rewrite the rules of this race against time. The XVIVO Heart Assist Transport™ utilizes an investigational method called Hypothermic Oxygenated Perfusion (HOPE). Instead of sitting static on ice, the donor heart is connected to a portable device that continuously circulates a cold, oxygenated, nutrient-rich solution through its vessels. This process is designed to keep the organ metabolically active but in a protected state, reducing the cellular damage that occurs during transport.

The PRESERVE Trial, which enrolled 141 transplant recipients across 14 U.S. centers, put this technology to the test. The preliminary results are compelling: nearly three-quarters (73.8%) of the hearts preserved using the HOPE method exceeded the traditional four-hour timeframe. More importantly, the outcomes were positive. The study met its primary efficacy endpoint—a composite measure including the absence of severe primary graft dysfunction at 30 days—with a 92.1% success rate, significantly outperforming its pre-specified goal. Furthermore, the patient survival rate at one year was 91.4%.

“The results of the PRESERVE Trial are encouraging,” Dr. Pretorius stated in the announcement. He noted that the technology is being studied for its potential to support the use of extended-criteria donor hearts, which could “expand access to lifesaving care for patients who may otherwise never receive an organ.”

Navigating a Competitive and Regulated Market

The potential approval of the XVIVO Heart Assist Transport would introduce a significant new player into the evolving organ preservation market. The company's primary competitor in the cardiac space is TransMedics, whose Organ Care System (OCS) is already FDA-approved. However, the two technologies employ fundamentally different approaches. While XVIVO uses hypothermic (cold) perfusion, the TransMedics OCS uses normothermic (warm) perfusion, keeping the heart beating in a near-physiologic state during transport.

The emergence of a competing technology based on a different scientific principle could provide transplant centers with more options tailored to specific clinical scenarios. The choice between cold and warm perfusion may depend on donor characteristics, expected transport time, and institutional protocols. This competition could also drive innovation and potentially lower costs over time.

Before it can reach the market, XVIVO must navigate the FDA's rigorous Pre-Market Approval (PMA) process, the most stringent pathway for medical devices. While the process can be lengthy, devices that address unmet needs for life-threatening conditions, like the XVIVO system, may be eligible for programs that accelerate review. The strong data from the PRESERVE trial will be central to the company's submission.

Economically, advanced perfusion systems carry a higher upfront cost than a standard cooler. However, healthcare systems are increasingly focused on value. By potentially reducing post-transplant complications like primary graft dysfunction, which leads to longer hospital stays and more intensive care, these technologies could prove cost-effective. Recent changes in Medicare reimbursement, which are beginning to cover ex-vivo perfusion disposables, signal a growing recognition of the long-term benefits of these advanced systems.

The Ripple Effect on Patients and Policy

Beyond the science and market dynamics, the ultimate impact of technologies like HOPE is measured in human lives. For the thousands of patients waiting for a new heart, an expanded organ pool is the most significant news possible. Safely extending preservation time means a heart from a donor in a remote location could reach a recipient hundreds of miles further away. It means hearts previously considered too marginal can now be considered viable candidates for transplantation.

"This type of technology doesn't just add a few hours; it changes the entire logistical and ethical calculus of organ allocation," commented one transplant surgeon not involved in the trial. "It gives us the flexibility to find the best possible match for a patient, not just the closest one. It forces us to re-evaluate our definitions of a 'viable' organ, which could lead to fundamental shifts in national allocation policies to ensure we are maximizing this incredible gift of life."

This added flexibility also eases the immense pressure on procurement and surgical teams, allowing for more deliberate planning and reducing the frantic rush that defines many transplant procedures. As XVIVO moves toward its FDA submission, the transplant community watches with anticipation, hopeful that a new era of organ preservation is on the horizon—one where the ticking clock is no longer the greatest adversary in the quest to save a life.